Moolec Science (MLEC)
NASDAQ:MLEC
Want to see MLEC full AI Analyst Report?
Top Page
Moolec Science
(NASDAQ:MLEC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$8.50
▲(106.81% Upside)
Action:ReiteratedDate:04/11/26
The score is held down primarily by weak financial health—large losses, ongoing cash burn, and a significantly weakened balance sheet with negative equity and high leverage. Technicals are also soft with the stock trading below key moving averages and negative MACD, while valuation support is limited given negative earnings and no dividend data.
Positive Factors
Commercialization traction
A dramatic revenue ramp and materially higher gross margin indicate the company is successfully converting engineered crop traits into ingredient sales. This suggests product-market fit and scalable unit economics as volumes increase, supporting sustainable revenue growth and future commercialization leverage.
Negative Factors
Negative equity & high debt
Substantially negative equity combined with large outstanding debt weakens the balance sheet and elevates refinancing and solvency risk. This structural leverage limits financial flexibility, increases the likelihood of dilutive capital raises, and may constrain investments needed for long-term commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercialization traction
A dramatic revenue ramp and materially higher gross margin indicate the company is successfully converting engineered crop traits into ingredient sales. This suggests product-market fit and scalable unit economics as volumes increase, supporting sustainable revenue growth and future commercialization leverage.
Read all positive factors
Moolec Science (MLEC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.53M
Dividend YieldN/A
Average Volume (3M)209.37K
Price to Earnings (P/E)―
Beta (1Y)-0.22
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding726,118
10 Day Avg. Volume506,476
30 Day Avg. Volume209,369
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.12
P/FCF Ratio-1.35
Enterprise Value/Market Cap38.70
Enterprise Value/Revenue32.25
Enterprise Value/Gross Profit-395.06
Enterprise Value/Ebitda-48.47
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Moolec Science Business Overview & Revenue Model
Company Description
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage th...
How the Company Makes Money
Moolec Science makes money primarily by developing and commercializing genetically engineered crops that produce value-added food ingredients, then monetizing the resulting ingredients and/or the underlying technology. Key revenue streams include:...
Moolec Science Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
14
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2024 | Sep 2023 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.83M | 333.61M | 5.63M | 905.05K | 0.00 | 0.00 |
| Gross Profit | -639.50K | 114.01M | 472.58K | -143.31K | 0.00 | 0.00 |
| EBITDA | -5.21M | -69.01M | -6.16M | -51.74M | -3.65M | -13.80K |
| Net Income | -8.28M | -111.46M | -7.31M | -51.79M | -4.53M | -13.80K |
Balance Sheet | ||||||
| Total Assets | 31.38M | 204.71M | 34.79M | 24.05M | 5.69M | 138.59M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 9.02M | 5.39M | 2.83M | 1.08M | 337.60K |
| Total Debt | 22.09M | 246.88M | 14.68M | 2.65M | 125.00K | 125.00K |
| Total Liabilities | 28.58M | 287.58M | 27.97M | 13.95M | 4.09M | 4.51M |
| Stockholders Equity | 2.80M | -65.97M | 6.82M | 10.11M | 1.60M | 134.08M |
Cash Flow | ||||||
| Free Cash Flow | -6.12M | -30.10M | -9.49M | -7.69M | -1.89M | -8.80K |
| Operating Cash Flow | -5.70M | -24.45M | -9.33M | -7.51M | -1.89M | -8.80K |
| Investing Cash Flow | -270.17K | -35.99M | 134.87K | -2.34M | -138.00M | 0.00 |
| Financing Cash Flow | 5.95M | 13.07M | 11.71M | 11.28M | 139.05M | 14.49K |
Moolec Science Technical Analysis
Negative
4.11
Price Trends
9.31
Negative
7.42
Negative
18.04
Negative
Market Momentum
-0.37
Positive
45.12
Neutral
16.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLEC, the sentiment is Negative. The current price of 4.11 is below the 20-day moving average (MA) of 7.68, below the 50-day MA of 9.31, and below the 200-day MA of 18.04, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 45.12 is Neutral, neither overbought nor oversold. The STOCH value of 16.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLEC.
Moolec Science Risk Analysis
Moolec Science disclosed 3 risk factors in its most recent earnings report. Moolec Science reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Auditors Q2, 2024
2.
Directors and Senior Management Q2, 2024
3.
Advisors Q2, 2024
Moolec Science Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $6.53M | -0.37 | -174.68% | ― | ― | ― | |
43 Neutral | $4.27M | -0.13 | 212.59% | ― | -48.24% | 62.05% | |
42 Neutral | $3.35M | -0.21 | -386.72% | ― | -2.75% | 68.01% | |
| ― | $14.38M | -1.16 | -24.80% | ― | 3.70% | 3.82% | |
41 Neutral | $2.27M | -0.52 | ― | ― | ― | 84.28% |
* Healthcare Sector Average
MLEC
Moolec Science
8.99
-101.98
-91.90%
AIM
AIM ImmunoTech
0.52
-6.92
-92.96%
ENSC
Ensysce Biosciences
0.36
-2.66
-88.05%
CYCN
Cyclerion Therapeutics
3.32
-0.13
-3.77%
CLDI
Calidi Biotherapeutics
0.21
-5.58
-96.41%
Moolec Science Corporate Events
Moolec Science Sets May 13, 2026 Virtual AGM to Approve 2025 Results and Board Slate
Apr 15, 2026
Moolec Science SA has filed a Form 6-K dated April 15, 2026, announcing that it will hold its annual general meeting of shareholders virtually on May 13, 2026, at 9:00 a.m. Eastern Time. The meeting will be accessible to registered and beneficial ...
Moolec Science Gains New Controlling Shareholder as AIGC Takes 65% Stake
Apr 2, 2026
On April 1, 2026, Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA, acquiring 65.1% of the company’s outstanding shares through a partial conversion of preference shares into ordinary shares. The tra...
Moolec Science Overhauls Board With New Quality-Focused Director
Feb 26, 2026
On February 25, 2025, Moolec Science SA, a plant- and microbe-based protein innovator for the global food industry, announced a reshaping of its board of directors. The company appointed U.S.-based quality and operations veteran Daniel Core to its...
Moolec Science Wins Conditional Nasdaq Listing Extension After Reverse Stock Split
Jan 30, 2026
On January 30, 2026, Moolec Science announced that a Nasdaq Hearings Panel has granted the company continued listing on the Nasdaq Stock Market, after Moolec regained compliance with the minimum bid price requirement on January 16, 2026, following...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.